S4
S49.F Supernus Pharmaceuticals Inc
- Market cap
- EUR 2.17B
- P/E
- -
- P/B
- 5.55x
- ROE
- -5.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is S49.F undervalued?
Graham numberThe Graham number of Supernus Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Supernus Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Supernus Pharmaceuticals Inc yet.
Supernus Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia in patients with Parkinson's disease (PD) receiving levodopa/carbidopa; Oxtellar XR, an extended-release oxcarbazepine product indicated for mono…
Full company profileSupernus Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Supernus Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 215M | 302M | 409M | 393M | 520M | 580M | 667M | 608M | 662M | 719M | 871M |
| Gross Profit | 203M | 287M | 394M | 376M | 468M | 505M | 580M | 524M | 584M | 644M | 759M |
| Operating Income | 54.2M | 99.5M | 144M | 149M | 176M | 79.5M | 45.6M | 13.4M | 75.6M | -36.9M | 18.3M |
| EBITDA | - | 110M | 165M | 177M | 211M | 129M | 150M | 90.0M | 178M | 42.5M | 50.2M |
| Net Income | 91.2M | 57.3M | 111M | 113M | 127M | 53.4M | 60.7M | 1.32M | 73.9M | -38.6M | -53.0M |
| EPS | - | 1.12 | 2.12 | 2.15 | 2.40 | 1.00 | 1.12 | 0.02 | 1.33 | -0.67 | -0.91 |
| Balance Sheet | |||||||||||
| Total Assets | 310M | 424M | 978M | 1.16B | 1.50B | 1.69B | 1.70B | 1.28B | 1.37B | 1.45B | 1.40B |
| Total Liabilities | 118M | 157M | 525M | 565M | 759M | 873M | 816M | 356M | 332M | 391M | 335M |
| Shareholders' Equity | 192M | 267M | 453M | 595M | 745M | 816M | 886M | 922M | 1.04B | 1.06B | 1.06B |
| Cash & Short-term Investments | 66.4M | 100M | 192M | 181M | 289M | 203M | 93.1M | 75.1M | 69.3M | 128M | 176M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 66.8M | 115M | 129M | 143M | 138M | 127M | 117M | 111M | 172M | 47.3M | 91.1M |
| Capital Expenditure | 1.60M | 2.03M | 844K | 1.39M | 3.69M | 2.05M | 412K | 551K | 725K | 1.34M | 307K |
| Free Cash Flow | - | 113M | 128M | 140M | 135M | 125M | 116M | 111M | 171M | 46.0M | 90.0M |
| Ratios | |||||||||||
| ROE | 47.6% | 21.4% | 24.5% | 19.0% | 17.0% | 6.5% | 6.9% | 0.1% | 7.1% | -3.6% | -5.0% |
| ROA | 29.5% | 13.5% | 11.4% | 9.7% | 8.4% | 3.2% | 3.6% | 0.1% | 5.4% | -2.7% | -3.8% |
| Net Profit Margin | 42.4% | 19.0% | 27.1% | 28.8% | 24.4% | 9.2% | 9.1% | 0.2% | 11.2% | -5.4% | -6.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Supernus Pharmaceuticals Inc dividends
Supernus Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns Supernus Pharmaceuticals Inc
- Insiders 4.32%
- Institutions 95.68%
- Public & others 0.00%
- Shares outstanding 58.2M
- Free float 51.9M
Supernus Pharmaceuticals Inc company profile
- Company name
- Supernus Pharmaceuticals Inc
- Ticker
- S49.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 778
- Fiscal year end
- December
- Address
- 9715 Key West Avenue, Rockville, MD, United States, 20850
- Phone
- 301 838 2500
- Website
- supernus.com
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia in patients with Parkinson's disease (PD) receiving levodopa/carbidopa; Oxtellar XR, an extended-release oxcarbazepine product indicated for monotherapy for partial-onset seizures; ZURZUVAE, a neuroactive steroid with GABAergic activity, for the treatment of postpartum depression (PPD) in adults; and APOKYN for the acute, intermittent treatment of hypomobility or off-episodes in patients with advanced PD. It also provides Trokendi XR, an extended-release topiramate product indicated for the treatment of epilepsy and for migraine prophylaxis; XADAGO for use with levodopa/carbidopa in patients with PD experiencing off-episodes; and MYOBLOC, a type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor in a Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in a Phase 2 clinical trial for treatment-resistant depression; and SPN-443, a stimulant in a Phase 1 trial for the treatment of ADHD and other CNS conditions. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of a Phase 2 clinical program for SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland. As of November 2, 2026, Supernus Pharmaceuticals, Inc. operates as a subsidiary of Indivior Pharmaceuticals, Inc.
Supernus Pharmaceuticals Inc management
9- Mr. Jack A. Khattar M.B.A.Founder, President, CEO, Secretary & Director · born 1961
- Mr. Timothy C. DecSenior VP & CFO · born 1959
- Dr. Padmanabh P. Bhatt Ph.D.Chief Scientific Officer & Senior VP of Intellectual Property · born 1957
- Mr. Frank MottolaSenior VP & Chief Technology Operations Officer · born 1972
- Dr. Jonathan Rubin M.B.A., M.D.Senior VP of Research & Development and Chief Medical Officer · born 1961
- Mr. Taylor RaifordSenior Vice President of Sales
- Dr. William Todd Horich M.B.A., Ph.D.Senior VP & Chief Commercial Officer · born 1973
- Dr. Bryan A. Roecklein Ph.D.Senior VP & Chief Business Officer · born 1959
- Mr. Jeff BozickSenior Vice President of Supply Chain